1+ day, 15+ min ago   (323+ words) Last week’s regulatory news saw the US Food and Drug Administration (FDA) grant accelerated approval for AstraZeneca’s Etcamah combination for the treatment of breast cancer. On the research front, Novartis suffered another setback, this time with its Phase III trial…...

3+ week, 2+ day ago   (588+ words) The Pharma Letter A clinical-stage biopharmaceutical company focused on WEE1 inhibition in biomarker-selected ovarian cancer, with its lead asset azenosertib approaching a pivotal registration-enabling data readout in 2026. Zentalis Pharmaceuticals discovers and develops small molecule therapeutics targeting fundamental biological pathways in cancer....

3+ week, 5+ day ago   (212+ words) thepharmaletter.com - OmniAb signs $370 million ion channel discovery deal with Eli Lilly California-based antibody discovery technology provider OmniAb (Nasdaq: OABI) has entered a global collaboration and license agreement with US pharma major Eli Lilly (NYSE: LLY) covering a new ion…...

4+ week, 1+ day ago   (314+ words) Deal-making news last week including Spanish dermatology specialist Almirall entering into a research collaboration with China’s CrystalO Biopharma. Sentynl entered a deal to license lung disease candidate alvelestat from Mereo BioPharma, which could earn the latter nearly half a billion…...